Four more Byetta deaths but Amylin and Lilly defend drug
Shares in Amylin have taken a bashing after the firm and partner Eli Lilly reported four new deaths among patients with pancreatitis who took their type II diabetes drug Byetta, in addition to the two cases reported last week
Adagio study shows Azilect slows progression of Parkinson’s
A bid by Israel's Teva and Denmark's Lundbeck to get expanded use of Azilect has been boosted by late-stage data which shows that the drug may slow the progression of Parkinson’s disease
FDA wants more info on J&J's once-monthly paliperidone drug
Johnson & Johnson’s hopes of getting a new schizophrenia drug onto the market have received a setback with the news that US regulators have asked for more information on the treatment
|
 |
B-MS/Pfizer's apixaban delayed after Phase III failure
Bristol-Myers Squibb and Pfizer have suffered a major setback after the firms said they will not be seeking approval for their anticoagulant apixaban in 2009, as expected, after the drug failed in a late-stage trial
US offers to help Pakistan set up drug regulatory agency
US Human Services Secretary Michael Leavitt has offered his government’s assistance to Pakistan in setting up a drug regulatory authority. Despite Pakistan’s soaring pharmaceutical exports, there is currently not a single manufacturing unit in the country which has been approved by the FDA
Governments urged to end inequalities in Parkinson’s care
A new awareness campaign has been launched which is aimed at persuading decision makers and politicians in Europe to end inequalities in care and treatment access for people with Parkinson's disease
|